Inhibitory effect of NPY on isoprenaline-induced osteoclastogenesis in mouse bone marrow cells

Biochimica et Biophysica Acta - General Subjects

Volumn 1770, Issue 6, 2007, Pages 966-973

  Amano, Shinobu ^a   Arai, Michitsugu ^a   Goto, Shigemi ^a   Togari, Akifumi ^a  

^a AICHI GAKUIN UNIVERSITY   (Japan)

Author keywords

Isoprenaline; Mouse bone marrow cell; Neuropeptide Y (NPY); Osteoclastogenesis

Indexed keywords

CALCITRIOL; CYCLIC AMP; FORSKOLIN; ISOPRENALINE; MESSENGER RNA; NEUROPEPTIDE Y; OSTEOCLAST DIFFERENTIATION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE MARROW CELL; CELL CULTURE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENYLATE CYCLASE; ADRENERGIC BETA-AGONISTS; ANIMALS; BONE MARROW CELLS; BONE RESORPTION; BUCLADESINE; CALCITRIOL; CELLS, CULTURED; ENZYME ACTIVATION; FORSKOLIN; ISOPROTERENOL; MALE; MICE; MICE, MUTANT STRAINS; NEUROPEPTIDE Y; OSTEOCLASTS; RANK LIGAND; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, NEUROPEPTIDE Y; VITAMINS;

EID: 34247250145     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2007.02.009     Document Type: Article

References (43)

1. Tatemoto K., Carlquist M., and Mutt V. Neuropeptide Y-A novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 296 (1982) 659-660
2. Gray T.S., and Morley J.E. Neuropeptide Y: anatomical distribution and possible function in mammalian nervous system. Life Sci. 38 (1986) 389-401
3. Michel M.C., Beck-Sickinger A., Cox H., Doods H.N., Herzog H., Larhammar D., Quirion R., Schwartz T., and Westfall T. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev. 50 (1998) 143-150
4. Gehlert D.R. Introduction to the reviews on neuropeptide Y. Neuropeptides 38 (2004) 135-140
5. Misra S., Murthy K.S., Zhou H., and Grider J.R. Coexpression of Y1, Y2 and Y4 receptors in smooth muscle coupled to distinct signaling pathway. J. Pharmacol. Ex. Ther. 311 (2004) 1154-1162
6. Straub R.H., Schaller T., Miller L.E., von Horsten S., Jessop D.S., Falk W., and Scholmerich J. Neuropeptide Y cotransmission with norepinephrine in the sympathetic nerve-macrophage interplay. J. Neurochem. 75 (2000) 2464-2471
7. Lundberg J.M., Anggard A., Pernow J., and Hokfelt T. Neuropeptide Y-, substance P- and VIP-immunoreactive nerves in cat spleen in relation to autonomic vascular and volume control. Cell Tissue Res. 239 (1985) 9-18
8. Weihe E., Nohr D., Michel S., Muller S., Zentel H.J., Fink T., and Krekel J. Molecular anatomy of the neuro-immune connection. Int. J. Neurosci. 59 (1991) 1-23
9. Jessop D., Biswas S., D'Souza L., Chowdrey H., and Lightman S. Neuropeptide Y immunoreactivity in the spleen and thymus of normal rats and following adjuvant-induced arthritis. Neuropeptides 23 (1992) 203-207
10. Sisask G., Bjurholm A., Ahmed M., and Kreicbergs A. The development of autonomic innervation in bone and joints of the rat. J. Auton. Nerv. Syst. 59 (1996) 27-33
11. Hill F.L., and Elde R. Distribution of CGRP-, VIP-, D beta H-, SP-, and NPY-immunoreactive nerves in the periosteum of the rat. Cell Tissue Res. 264 (1991) 469-480
12. Bjurholm A., Kreicbergs A., Terenius L., Goldstein M., and Schultzberg M. Neuropeptide Y-, tyrosine hydroxylase- and vasoactive intestinal polypeptide-immunoreactive nerves in bone and surrounding tissues. J. Auton. Nerv. Syst. 25 (1988) 119-125
13. Chenu C. Role of innervation in the control of bone remodeling. J. Musculoskel. Neuron Interact. 4 (2004) 132-134
14. Togari A., Arai M., Mizutani S., Mizutani S., Koshihara Y., and Nagatsu T. Expression of mRNAs for neuropeptide receptors and beta-adrenergic receptors in human osteoblasts and human osteogenic sarcoma cells. Neurosci. Lett. 233 (1997) 125-128
15. Takeda S., Elefteriou F., Levasseur R., Liu X., Zhao L., Parker K.L., Armstrong D., Ducy P., and Karsenty G. Leptin regulates bone formation via the sympathetic nervous system. Cell 111 (2002) 305-317
16. Harfstrand A., Fredholm B., and Fuxe K. Inhibitory effects of neuropeptide Y on cyclic AMP accumulation in slices of the nucleus tractus solitarious region of the rat. Neurosci. Lett. 76 (1987) 185-190
17. von Valen F., Keck E., and Jurgens H. Neuropeptide Y inhibits vasoactive intestinal peptide- and dopamine-induced cyclic AMP formation in human Ewing's sarcoma WE-68 cells. FEBS Lett. 249 (1989) 271-274
18. Bjurholm A., Kreicbergs A., Schultzberg M., and Lerner U.H. Neuroendocrine regulation of cyclic AMP formation in osteoblastic cell lines (UMR-106-01, ROS 17/2.8, MC3T3-E1, and Saos-2) and primary bone cells. J. Bone Miner. Res. 7 (1992) 1011-1019
19. Harada Y., Okubo M., Yaga K., Kaneko T., and Kaku K. Neuropeptide Y inhibits β-adrenergic agonist- and vasoactive intestinal peptide-induced cyclic AMP accumulation in rat pinealocytes through pertussis toxin-sensitive G protein. J. Neurochem. 59 (1992) 2178-2183
20. Togari A. Adrenergic regulation of bone metabolism: possible involvement of sympathetic innervation of osteoblastic and osteoclastic cells. Microsc. Res. Tech. 58 (2002) 77-84
21. Togari A., Arai M., and Kondo A. The role of the sympathetic nervous system in controlling bone metabolism. Expert Opin. Ther. Targets 9 (2005) 931-940
22. Elefteriou F., Ahn J.D., Takeda S., Starbuck M., Yang X., Liu X., Kondo H., Richards W.G., Bannon T.W., Noda M., Clement K., Vaisse C., and Karsenty G. Leptin regulation of resorption by the sympathetic nervous system and CART. Nature 434 (2005) 514-520
23. Kondo A., and Togari A. In vivo stimulation of sympathetic nervous system modulates osteoblastic activity in mouse calvaria. Am. J. Physiol.: Endocrinol. Metab. 285 (2003) E661-E667
24. Inoue H., Kondo A., and Togari A. Activation of the peripheral sympathetic nervous system increased the expression of cyclooxygenase-2 (COX-2) mRNA in mouse calvaria. Neurosci. Lett. 338 (2003) 37-40
25. Cherruau M., Facchinetti P., Baroukh B., and Saffar J.L. Chemical sympathectomy impairs bone resorption in rats: a role for the sympathetic system on bone metabolism. Bone 25 (1999) 545-551
26. Moore R.E., Smith II C.K., Biley C.S., Voelkel E.F., and Tashian Jr. A.H. Characterization of beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture. Bone Miner. 23 (1993) 301-315
27. Takeuchi T., Tsuboi T., Arai M., and Togari A. Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. Biochem. Pharmacol. 61 (2001) 579-586
28. Ishizuka K., Hirukawa K., Nakamura H., and Togari A. Inhibitory effect of CGRP osteoclast formation by mouse bone marrow cells treated with isoproterenol. Neurosci. Lett. 379 (2005) 47-51
29. Arai M., Nagasawa T., Koshihara Y., Yamamoto S., and Togari A. Effects of β-adrenergic agonists on bone-resorbing activity in human osteoclast-like cells. Biochim. Biophys. Acta 1640 (2003) 137-142
30. Roodman GD. Regulation of osteoclast differentiation. Ann. N. Y. Acad. Sci. 1068 (2006) 100-109
31. Takahashi N., Udagawa N., and Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem. Biophys. Res. Commun. 256 (1999) 449-455
32. Asagiri M., and Takayanagi H. The molecular understanding of osteoclast function. Bone 40 (2007) 251-264
33. Takami M., Cho E.S., Lee S.Y., Kamijo R., and Yim M. Phosphodiesterase inhibitors stimulate osteoclast formation via TRACE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways. FEBS Lett. 579 (2005) 832-838
34. Takahashi N., Yamana H., Yoshiki S., Roodman G.D., Mundy G.R., Boyde S.J., and Suda T. Osteoclast-like cell formation and its regulation by osteotrophic hormones in mouse bone marrow cultures. Endocrinology 122 (1988) 1373-1382
35. Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162 (1987) 156-159
36. Togari A., Ichinose H., Matsumoto S., Fujita K., and Nagatsu T. Multiple mRNA forms of human GTP cyclohydrolase I. Biochem. Biophys. Res. Commun. 187 (1992) 359-365
37. Minkin C. Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif. Tissue Int. 34 (1982) 285-290
38. Kondo H., Guo J., and Bringhurst F.R. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. J. Bone Miner. Res. 17 (2002) 1667-1679
39. Kaji H., Sugimoto T., Kanatani M., Fukase M., Kumegawa M., and Chihara K. Prostaglandin E2 stimulates osteoclast-like cell formation and bone-resorbing activity via osteoblasts: role of cAMP-dependent protein kinase. J. Bone Miner. Res. 11 (1996) 62-71
40. Penn R.B., Panettieri Jr. R.A., and Benovic J.L. Mechanisms of acute desensitization of the β2-AR-adenylyl cyclase pathway in human airway smooth muscle. Am. J. Respir. Cell Mol. Biol. 19 (1998) 338-348
41. Kellenberger S., Muller K., Richener H., and Bilbe G. Formoterol and isoproterenol induce c-fos gene expression in osteoblast-like cells by activating beta2-adrenergic receptors. Bone 22 (1998) 471-478
42. Millar B.C., Weis T., Piper H.M., Weber M., Borchard U., McDermott B.J., and Balasubramaniam A. Positive and negative contractile effects of neuropeptide Y on ventricular cardiomyocytes. Am. J. Physiol. 261 (1991) H1727-H1733
43. Gulbenkian S., Edvinsson L., Saetrum O.O., Valenca A., Wharton J., and Polak J.M. Neuropeptide Y modulates the action of vasodilator agents in guinea-pig epicardial coronary arteries. Regul. Pept. 40 (1992) 351-362